Sofiane Bendifallah1, Lobna Ouldamer2, Vincent Lavoue3, Geoffroy Canlorbe4, Emilie Raimond5, Charles Coutant6, Olivier Graesslin5, Cyril Touboul7, Pierre Collinet8, Emile Daraï9, Marcos Ballester9. 1. Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), France; INSERM UMR_S_707, "Epidemiology, Information Systems, Modeling", University Pierre and Marie Curie, Paris 6, France. Electronic address: sofiane.bendifallah@aphp.fr. 2. Department of Obstetrics and Gynaecology, Centre hospitalier régional universitaire de Tours, hôpital Bretonneau, Tours, France. 3. CRLCC Eugène-Marquis, Service de Gynécologie, CHU de Rennes, Université de Rennes 1, France. 4. Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), France. 5. Department of Obstetrics and Gynaecology, Institute Alix de Champagne University Hospital, Reims, France. 6. Centre de lutte contre le cancer Georges François Leclerc, Dijon, France. 7. Department of Obstetrics and Gynecology, Centre Hospitalier Intercommunal, Créteil, France. 8. Department of Obstetrics and Gynecology, Centre Hospitalier Régional Universitaire, Lille, France. 9. Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), France; INSERM UMR_S_938, University Pierre et Marie Curie, Paris 6, France.
Abstract
OBJECTIVES: The purpose of this study was to analyse the endometrial cancer (EC) patterns of recurrence based on a large French multicentre database according to ESMO-ESGO-ESTRO classification. METHODS: Data of women with histologically proven EC who received primary surgical treatment between January 2001 and December 2012 were retrospectively abstracted from seven institutions with prospectively maintained databases. The endpoints were recurrence, recurrence free survival (RFS) and overall survival (OS). Time to the first EC recurrence in a specific site was evaluated by using cumulative incidence analysis (Gray's test). RESULTS: Data from 829 women were analysed in whom recurrences were observed in 176 (21%) with a median and mean time to recurrence of 13 and 19.5months, respectively. High (35%) and high-intermediate risk groups (16%) were associated with higher recurrence rates compared with low (9%) and intermediate (9%) risk patients (p<0.0001). Women with high risk EC had a higher 5-year cumulative incidence of distant recurrence (20.7%) than women with high-intermediate, intermediate and low risk EC (5.6%, 3.5%, 3.3%), (p<0.001), respectively. Women with high risk and high-intermediate risk EC had a higher 5-year cumulative incidence of loco-regional recurrence (24.3% and 16.6%, respectively) than women with intermediate and low risk EC (6.6% and 6.5%, respectively), (p<0.001). CONCLUSIONS: We report specific time and site patterns of first recurrence according to the ESMO/ESGO/ESTRO classification. Sites and hazard rates for recurrence differ widely between subgroups over time. Defining patterns of EC recurrence may provide useful information for developing follow-up recommendations and designing therapeutic approaches.
OBJECTIVES: The purpose of this study was to analyse the endometrial cancer (EC) patterns of recurrence based on a large French multicentre database according to ESMO-ESGO-ESTRO classification. METHODS: Data of women with histologically proven EC who received primary surgical treatment between January 2001 and December 2012 were retrospectively abstracted from seven institutions with prospectively maintained databases. The endpoints were recurrence, recurrence free survival (RFS) and overall survival (OS). Time to the first EC recurrence in a specific site was evaluated by using cumulative incidence analysis (Gray's test). RESULTS: Data from 829 women were analysed in whom recurrences were observed in 176 (21%) with a median and mean time to recurrence of 13 and 19.5months, respectively. High (35%) and high-intermediate risk groups (16%) were associated with higher recurrence rates compared with low (9%) and intermediate (9%) risk patients (p<0.0001). Women with high risk EC had a higher 5-year cumulative incidence of distant recurrence (20.7%) than women with high-intermediate, intermediate and low risk EC (5.6%, 3.5%, 3.3%), (p<0.001), respectively. Women with high risk and high-intermediate risk EC had a higher 5-year cumulative incidence of loco-regional recurrence (24.3% and 16.6%, respectively) than women with intermediate and low risk EC (6.6% and 6.5%, respectively), (p<0.001). CONCLUSIONS: We report specific time and site patterns of first recurrence according to the ESMO/ESGO/ESTRO classification. Sites and hazard rates for recurrence differ widely between subgroups over time. Defining patterns of EC recurrence may provide useful information for developing follow-up recommendations and designing therapeutic approaches.
Authors: Austin B Gardner; Lindsey M Charo; Amandeep K Mann; Daniel S Kapp; Ramez N Eskander; John K Chan Journal: Clin Exp Metastasis Date: 2019-11-22 Impact factor: 5.150
Authors: Lea A Moukarzel; Kenya F Braxton; Quin C Zhou; Silvana Pedra Nobre; Alexia Iasonos; Kaled M Alektiar; William P Tew; Nadeem R Abu-Rustum; Mario M Leitao; Dennis S Chi; Jennifer J Mueller Journal: Gynecol Oncol Date: 2021-06-02 Impact factor: 5.304
Authors: Renata Rodrigues da Cunha Colombo Bonadio; Renata Gondim Meira Velame Azevedo; Guilherme Harada; Samantha Cabral Severino da Costa; Vanessa Costa Miranda; Daniela de Freitas; Elias Abdo Filho; Patricia Alves de Oliveira Ferreira; Flavia Gabrielli; Maria Del Pilar Estevez Diz Journal: J Glob Oncol Date: 2018-09